ADVERTISEMENT
Gland Pharma Gets Yes Securities' 'Add' Upgrade; Sees U.S., Cenexi Business as Key Growth Drivers
Yes Securities views Gland Pharma as a better proxy on US generics in the near term, hence hikes target price.
16 Sep 2025, 10:52 AM IST 
Save
Gland Pharma's US business would see launch of 2 key products – Dalbavancin and Norepinephrine and 5-6% volume increase that would drive growth in the range of 11%.
(Photo Source: Gland Pharma website).
Gland Pharma would have ~140 million unit vial/pens capacity by Mar’26 of which company intends to utilize ~20 mn in FY27 as it targets the initial GLP-1 opportunity in the form of Liraglutide and Semaglutide in emerging markets.
